论文部分内容阅读
目的探讨改良奥沙利铂联合替加氟、亚叶酸钙(FOLFOX)方案治疗大肠癌患者的临床效果。方法选取2012年1月至2015年1月黑山县第一人民医院收治的大肠癌患者46例为研究对象,按随机数字表法分为研究组和对照组,每组23例。研究组患者给予改良FOLFOX方案治疗,对照组患者给予常规奥沙利铂、亚叶酸钙、氟尿嘧啶方案治疗,比较两组患者治疗有效率、不良反应发生情况及生命质量变化情况。结果研究组患者治疗总有效率为87.0%,对照组患者治疗总有效率为56.5%,两组差异有统计学意义(P<0.05);研究组患者白细胞减少、恶心呕吐、神经毒性、腹泻、口腔黏膜炎等不良反应发生率均低于对照组,差异均有统计学意义(均P<0.05);研究组患者贫血、血小板减少、手足综合征等不良反应发生率与对照组比较,差异均无统计学意义(均P>0.05);治疗前,两组患者KPS评分比较,差异无统计学意义(P>0.05);治疗后,研究组患者KPS评分优于对照组,差异有统计学意义(P<0.05)。结论改良FOLFOX方案在大肠癌患者中的应用效果显著,不良反应相对较少,能够显著改善患者的生命质量。
Objective To investigate the clinical effect of oxaliplatin combined with tegafur and leucovorin (FOLFOX) in the treatment of patients with colorectal cancer. Methods Forty-six patients with colorectal cancer who were treated in First People’s Hospital of Heishan County from January 2012 to January 2015 were selected as the study group and divided into study group and control group according to random number table method, with 23 cases in each group. Patients in the study group were treated with modified FOLFOX regimen. Patients in the control group were treated with conventional oxaliplatin, leucovorin and fluorouracil. The treatment efficiency, adverse reactions and quality of life were compared between the two groups. Results The total effective rate was 87.0% in the study group and 56.5% in the control group, with significant difference between the two groups (P <0.05). In the study group, leukopenia, nausea and vomiting, neurotoxicity, diarrhea, Oral mucositis and other adverse reactions were lower than the control group, the difference was statistically significant (all P <0.05); the study group patients with anemia, thrombocytopenia, hand-foot syndrome and other adverse reactions compared with the control group, the difference was There was no significant difference between the two groups (P> 0.05). Before treatment, there was no significant difference in KPS score between the two groups (P> 0.05). After treatment, KPS score of the study group was better than that of the control group, the difference was statistically significant (P <0.05). Conclusion The modified FOLFOX regimen is effective in treating patients with colorectal cancer with relatively few adverse reactions and can significantly improve the quality of life of patients.